Revised: 24 July 2018

Committees

Secretary’s note

As of November 2017, the Natural Health Products Bill is no longer on the legislative programme. The Ministry of Health is awaiting further information from the Government on the next steps for natural health products

Proposed AGENDA FOR THE 56TH MEETING OF THE MEDICINES CLASSIFICATION COMMITTEE on Natural Health Products (POSTPONED UNTIL THE nATURAL hEALTH pRODUCTS bILL HAS IT’S THIRD READING

1

Welcome

2

Apologies

3

Confirmation of the minutes

4

Declaration of conflicts of interest

5

Matters arising

5.1

Matters arising for information

6

Submissions for reclassification

6.0.1

Background on Natural Health Products Bill

This is a background paper (PDF 101 KB, 3 pages) on the Natural Health Products Bill.

6.1

Boron - proposal to increase the limit for recommended daily dose in unscheduled medicines for internal use from 6 mg to 9 mg

This is a submission (PDF 88 KB, 7 pages) that proposes to allow medicines where the maximum daily dose contains 9 mg or less of boron to be unscheduled, so boron can be used in natural health products for oral use at this level.

6.2

Folic acid - proposal to increase the limit for recommended daily dose in unscheduled medicines for internal use to 1000 mcg

This is a submission (PDF 123 KB, 12 pages) that proposes to allow medicines where the maximum daily dose contains 1000 mcg or less of folic acid to be unscheduled, so folic acid can be used in natural health products for oral use at this level.

6.3

Iodine - proposal to increase the limit for recommended daily dose in unscheduled medicines for internal use from 300 mcg to 800 mcg

This is a submission (PDF 101 KB, 8 pages) that proposes to allow medicines where the maximum daily dose contains 800 mcg or less of iodine to be unscheduled, so iodine can be used in natural health products for oral use at this level.

6.4

Iron - proposal to increase the limit for recommended daily dose in unscheduled medicines for internal use from 24 mg to 45 mg

This is a submission (PDF 127 KB, 10 pages) that proposes to allow medicines where the maximum daily dose contains 45 mg or less of iron to be unscheduled, so iron can be used in natural health products for oral use at this level.

6.5

Lithium - proposal to change the classification from prescription medicine to unscheduled medicine when the recommended daily dose in medicines for internal use contains 3 mg or less

This is a submission (PDF 93 KB, 8 pages) that proposes to allow medicines where the maximum daily dose contains 3 mg or less of lithium to be unscheduled, so lithium can be used in natural health products for oral use at this level.

6.6

Natamycin - proposal to change the classification from prescription medicine to unscheduled medicine when the recommended daily dose in medicines for internal use contains 3 mg or less

This is a submission (PDF 1.14 MB, 31 pages) that proposes to allow medicines where the recommended daily dose contains 3 mg or less of natamycin to be unscheduled, so natamycin can be present in natural health products for oral use.

6.7

Potassium - proposal to increase the limit for recommended daily dose in unscheduled medicines for internal use from 100 mg to 3000 mg

This is a submission (PDF 107 KB, 9 pages) that proposes to allow medicines where the maximum daily dose contains 3000 mg or less of potassium to be unscheduled, so potassium can be used in natural health products for oral use at this level.

6.8

Selenium - proposal to increase the limit for recommended daily dose in unscheduled medicines for internal use from 150 mcg to 200 mcg

This is a submission (PDF 176 KB, 13 pages) that proposes to allow medicines where the maximum daily dose contains 200 mcg or less of selenium to be unscheduled, so selenium can be used in natural health products for oral use at this level.

6.9

Vitamin A - proposal to increase the limit for recommended daily dose in unscheduled medicines for internal use from 3 mg retinol equivalents (10,000 IU) to 6 mg retinol equivalents (20,000 IU)

This is a submission (PDF 147 KB, 11 pages) that proposes to allow medicines where the maximum daily dose contains 6 milligrams or less of retinol equivalents to be unscheduled, so Vitamin A can be used in natural health products for oral use at this level.

6.10

Vitamin D - proposal to increase the limit for recommended daily dose in unscheduled medicines for internal use from 25 mcg Vitamin D (1000 IU) to 75 mcg Vitamin D (3000 IU)

This is a submission (PDF 252 KB, 24 pages) that proposes to allow medicines where the maximum daily dose contains 75 mcg or less of Vitamin D to be unscheduled, so Vitamin D can be used in natural health products for oral use at this level.

6.11

Zinc - proposal to increase the limit for recommended daily dose in unscheduled medicines for internal use from 25 mg to 50 mg

This is a submission (PDF 120 KB, 11 pages) that proposes to allow medicines where the maximum daily dose contains 50 mgor less of zinc to be unscheduled, so zinc can be used in natural health products for oral use at this level.

7

Agenda items for the next meeting

8

General business

9

Date of the next meeting
Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /